Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $21.29

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned an average rating of “Buy” from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $21.29.

STOK has been the subject of a number of recent research reports. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Chardan Capital assumed coverage on shares of Stoke Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $24.00 target price on the stock. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the sale, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. The trade was a 16.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,786 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $88,150.14. Following the transaction, the chief executive officer now owns 61,885 shares in the company, valued at approximately $803,886.15. This represents a 9.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,849 shares of company stock valued at $809,421. 11.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in STOK. Bank of New York Mellon Corp grew its stake in Stoke Therapeutics by 28.9% in the second quarter. Bank of New York Mellon Corp now owns 115,892 shares of the company’s stock valued at $1,566,000 after purchasing an additional 25,988 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Stoke Therapeutics during the 2nd quarter worth approximately $123,000. Rhumbline Advisers lifted its position in Stoke Therapeutics by 14.3% during the second quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock valued at $647,000 after acquiring an additional 5,990 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in Stoke Therapeutics by 7.2% in the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock valued at $902,000 after acquiring an additional 4,508 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in Stoke Therapeutics in the second quarter worth $29,000.

Stoke Therapeutics Price Performance

Shares of STOK opened at $9.00 on Monday. The stock has a market capitalization of $476.70 million, a price-to-earnings ratio of -4.29 and a beta of 0.95. Stoke Therapeutics has a 1 year low of $4.09 and a 1 year high of $17.58. The business’s 50 day simple moving average is $11.91 and its 200-day simple moving average is $13.04.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. On average, sell-side analysts expect that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.